Increased thrombin generation and complement activation in patients with type IIA hyperlipoproteinemia: Effects of simvastatin treatment

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 10, 1997, Pages 706-723

  Di Garbo, Vincenzo ^a   Cordova, Rosamaria ^a   Avellone, Gino ^a,b  

^a UNIVERSITY OF PALERMO   (Italy)

^b NONE   (Italy)

Author keywords

Coagulation; Complement; Fibrinolysis; Hypercholesterolemia; Simvastatin

Indexed keywords

SIMVASTATIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; MALE; PRIORITY JOURNAL; THROMBOGENESIS;

EID: 0030710455     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80105-1     Document Type: Article

References (65)

1. Ross R. The pathogenesis of atherosclerosis: An update. NEJM. 1986;14:488-500.
2. Meade TW, Ruddock V, Stirling Y, et al. Fibrinolytic activity, clotting factor and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-1079.
3. Heinrich J, Balleisen L, Shulte H, et al. Fibrinogen and factor VII in the prediction of coronary risk: Results from the PROCAM study in healthy men. Arterioscler Thromb. 1994;14:54-59.
4. Cortellaro M, Boschetti C, Cofrancesco E, et al. The PLAT Study: A multidisciplinary study of hemostatic function and conventional risk factors in vascular disease patients. Atherosclerosis. 1991;90:109-118.
5. Miller GJ, Martin JC, Webster J, et al. Association between dietary fat intake and plasma Factor VII coagulant activity. Atherosclerosis. 1986;60:269-277.
6. Tremoli E, Maderna P, Colli S, et al. Increased platelet sensitivity and thromboxane formation in type II hyperlipoproteinaemic patients. Eur J Clin Invest. 1984;14:329-333.
7. Davi G, Averna M, Catalano I, et al. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation. 1992;85:1792-1798.
8. Mussoni L, Mannucci L, Sirtori M, et al. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb. 1992;12:19-27.
9. Avellone G, Di Garbo V, Cordova R, et al. Fibrinolysis in hypertriglyceridaemic subjects in response to venous occlusion. Blood Coagul Fibrinolysis. 1993;4:429-433.
10. Isaacsohn JL, Setaro JF, Nicholas C, et al. Effect of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am J Cardiol. 1994;74:735-736.
11. Seifert S, Kazatchkine MD. The complement system and atherosclerosis. Atherosclerosis. 1988;73:91-104.
12. Marder SR, Chenoweth DE, Goldestein M, Perez HD. Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a desArg. J Immunol. 1985;134:3325-3331.
13. Muscari A, Bozzoli C, Gerratana C, et al. Association of serum IgA and C4 with severe atherosclerosis. Atherosclerosis. 1988;74:179-186.
14. Muscari A, Bozzoli C, Puddu GM, et al. Association of serum C3 levels with the risk of myocardial infarction. Am J Med. 1995;98:357-364.
15. WHO Memorandum. Classification of hyperlipoproteinemias. Circulation. 1972;45:501-508.
16. Pignoli P, Tremoli E, Poli A, et al. Intimai plus medial thickness of the arterial wall: A direct measurement with ultrasound imaging. Circulation. 1986;74:1399-1403.
17. Prisco D, Paniccia R, Guarnaccia V, et al. Thrombin generation after physical exercise. Thromb Res. 1993;69:159-164.
18. Roschlau P, Bert E, Gruber W. Enzymatische Bestimmung des Gesamt-Cholesterins in Serum. Z Klin Chem Klin Biochem. 1974;12:403-407.
19. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem. 1973;19:476-482.
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of the low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
21. Mancini M, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single immunodiffusion. Immunochemistry. 1965;2:235-254.
22. Giacherio D, Matz K. Evaluation of an enzyme immunoassay kit for the determination of lipoprotein(a). Clin Chem. 1990;36:955-960.
23. Østerud B, Rapaport SI. Synthesis of intrinsic factor X activator. Inhibition of function of formed activator by antibodies to Factor VIII and Factor IX. Biochemistry. 1970;9:1854-1861.
24. Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin activation fragment F1 + 2 in plasma with an antibody against a synthetic peptide. Thromb Haemost. 1991;65:153-159.
25. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost. 1988;59:101-106.
26. Abildgaard U, Lie M, Odegard OR. A simple amidolytic method for the determination of functional active antithrombin III. Scand J Clin Lab Invest. 1976;36:109-112.
27. D'Angelo A, Gerosa S, Vigano' D'Angelo S, et al. Protein S and Protein C anticoagulant activity in acute and chronic cardiac ischemic syndromes. Relationship to inflammation, complement activation and in vivo thrombin activity. Thromb Res. 1994;75:133-142.
28. Wintrobe MM, Lee GR, Bogg DR. Clinical Haematology. Philadelphia: Lea and Febiger, 1981.
29. Bergsdorf N, Nilsson T, Wallen P. An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease. Thromb Haemost. 1983;50:740-744.
30. Stief TW, Lenz P, Becker U, Heimburger N. Determination of plasminogen activator inhibitor (PAI) capacity of human in presence of oxidants: A novel principle. Thromb Res. 1988;50:559-573.
31. Friberger P, Knos M, Gustavsson S, et al. Methods for determination of plasmin, anti-plasmin and plasminogen by means of substrate S-2251. Haemostasis. 1978;7:138-145.
32. Halbmayer W-M, Haushofer A, Schratzberger W, et al. Assessment of lupus anticoagulants within the routine coagulation laboratory-evaluation of 36 patients suffering from systemic lupus erythematosus. Med Klin. 1993;88:417-422.
33. Rosen S, Johansson K, Lindberg K, Dahlbäck B for the APC Resistance Study Group. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasma from healthy individuals. Thromb Haemost. 1994;72:255-260.
34. Speiser W, Speiser P, Minar E, et al. Activation of coagulation and fibrinolysis in patients with arteriosclerosis: Relation to localization of vessel disease and risk factors. Thromb Res. 1990;59:77-88.
35. Tanaka M, Suzuki A. Hemostatic abnormalities in acute myocardial infarction as detected by specific blood markers. Thromb Res. 1994;76:289-298.
36. Folsom AR, Wu KK, Shahar E, Davis CE. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb. 1993;13:1829-1836.
37. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet. 1987;330:3-9.
38. Jansson J-H, Olofsson B-O, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation. 1993;88:2030-2034.
39. Glueck CJ, Rorick MH, Schmerler M, et al. Hypofibrinolytic and atherogenic risk factors for stroke. J Lab Clin Med. 1995;125:319-325.
40. Kruskal JB, Commerford PJ, Franks JJ, Kirsch RE. Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. NEJM. 1987;317: 1361-1365.
41. Ceriello A, Taboga C, Giacomello R, et al. Fibrinogen plasma levels as a marker of thrombin activation in diabetes. Diabetes. 1994;43:430-432.
42. Hoek YA, Sturk A, Ten Cate JW, et al. Laboratory and clinical evaluation of an assay of thrombin-antithrombin III (TAT) complexes in plasma. Clin Chem. 1988;34:2058-2062.
43. Bauer KA, Rosenberg RD. The pathophysiology of prothrombotic state humans: Insights gained from studies using markers of hemostatic system activation. Blood. 1987;70:343-350.
44. Smith EB, Keene GA, Grant A, Stirk G. Fate of fibrinogen in human arterial intima. Arteriosclerosis. 1990;10:263-274.
45. Avellone G, Di Garbo V, Cordova R, et al. Activation of coagulation but normal fibrinolysis in patients with type IIa hyperlipoproteinemia. Thromb Res. 1996;81:277-282.
46. Spath P, Gabi F. Critical role of the conversion of the third complement component C3 (ß1C/ß1A) for its immunochemical quantitation. Clin Chim Acta. 1976;73:171-175.
47. Warren HD, Pantazis P, Davies PF. The third component of complement is transcribed and secreted by cultured human endothelial cells. Am J Pathol. 1987;129:9-12.
48. Gilligan DM, Guetta V, Panza JA, et al. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation. 1994;90:35-41.
49. Rapaport SI, Rao VM. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb. 1992;12:1111-1121.
50. Neri Serneri GG. Coronary thrombosis: Plaque rupture or acute inflammatory reaction? In: Neri Serneri GG, Gensini GF, Abbate R, Prisco D, eds. Atherosclerosis Inflammation and Thrombosis. Florence, Italy: Scientific Press; 1993:185-200.
51. Siess W. Molecular mechanism of platelet activation. Physiol Rev. 1989;69:58-178.
52. Ernst E. Plasma fibrinogen - an independent cardiovascular risk factor. J Intern Med. 1990;27:365-372.
53. Folsom AR, Wu KK, Davis CE, et al. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis. 1991;91:191-205.
54. Mennen LI, Schouten EG, Grobbee DE, Kluft C. Coagulation factor VII, dietary fat and blood lipids: A review. Thromb Haemost. 1996;76:492-499.
55. Hidaka Y, Eda T, Yonemoto M, Kamei T. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). Atherosclerosis. 1992;95:87-94.
56. Tremoli E, Colli S, Camera M, et al. Effects of vastatin on procoagulant and fibrinolytic properties of endothelial cells and macrophages. Proceedings of the 66th Congress of European Atherosclerosis Society, July 13-17, 1996; Florence, Italy. Abstract 45.
57. Andersen P, Arnesen H, Hjermann I. Hyperlipoproteinaemia and reduced fibrinolytic activity in healthy coronary high-risk men. Acta Med Scand. 1981;209:199-202.
58. Simpson HCR, Meade TW, Stirling Y, et al. Hypertriglyceridaemia and hypercoagulability. Lancet. 1983;321:786-790.
59. Jennings I, Luddington RJ, Harper PL. Changes in endothelial-related coagulation proteins in response to venous occlusion. Thromb Haemost. 1991;65:374-376.
60. Juan-Vague I, Alessi MC. Plasminogen activator inhibitor-1 and atherothrombosis. Thromb Haemost. 1993;70:138-143.
61. Panchenko E, Dobrovolsky A, Davletov K, et al. D-dimer and fibrinolysis in patients with various degrees of atherosclerosis. Eur Heart J. 1995;16:38-42.
62. Sawa H, Sobel BE, Fujii S. Potentiation by hypercholesterolemia of the induction of aortic intramural synthesis of plasminogen activator inhibitor type 1 by endothelial injury. Circ Res. 1993;73:671-680.
63. Lee AJ, Fowkes FG, Lowe GDO, Rumley A. Fibrin D-Dimer, haemostatic factors and peripheral arterial disease. Thromb Haemost. 1995;74:828-832.
64. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
65. Lacoste L, Lam JYT, Hung J, et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 1995;92: 3172-3177.